Enlivex: Meet The Company Championing A Paradigm Shift In Cancer Treatment

Sign up for this week’s All Access giveaway here

Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics Ltd. ENLV, was a guest on Benzinga’s All Access on November 11, 2022.

Enlivex creates novel therapeutics for serious diseases like cancer, primarily through a process known as macrophage reprogramming. This innovative technology has led to the development of the company’s flagship product, Allocetra. The drug has shown very promising results in clinical trials thus far.

Watch the full interview here:

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

ENLV Logo
ENLVEnlivex Therapeutics Ltd
$1.050.49%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
22.03
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...